The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer
Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2017-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_d4e077f9940c48a8880784b7e7c30b23 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Aurelio Bartolome Castrellon |e author |
| 700 | 1 | 0 | |a Ihor Pidhorecky |e author |
| 700 | 1 | 0 | |a Vicente Valero |e author |
| 700 | 1 | 0 | |a Luis Estuardo Raez |e author |
| 245 | 0 | 0 | |a The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer |
| 260 | |b Frontiers Media S.A., |c 2017-03-01T00:00:00Z. | ||
| 500 | |a 10.4081/oncol.2017.324 | ||
| 500 | |a 1970-5557 | ||
| 500 | |a 1970-5565 | ||
| 520 | |a Triple negative breast (TNBC) cancer constitutes a heterogeneous group of disease with histologic and molecular differences. Complete pathologic response to neoadjuvant chemotherapy (NACT) in TNBC is associated with improved outcomes. Efforts have been made in identifying drug combinations that will increase the response rate to preoperative chemotherapy. In this review we present recent studies that have incorporated carboplatin (Cb) in the NACT of TNBC. We discuss the homologous recombination deficiency score and the somatic or germline mutation for BRCA as potential biomarkers for future selection of patients that could benefit from the addition of Cb to NACT. | ||
| 546 | |a EN | ||
| 690 | |a Breast cancer | ||
| 690 | |a neoadjuvant chemotherapy | ||
| 690 | |a platinum agents. | ||
| 690 | |a Other systems of medicine | ||
| 690 | |a RZ201-999 | ||
| 690 | |a Internal medicine | ||
| 690 | |a RC31-1245 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Oncology Reviews, Vol 11, Iss 1 (2017) | |
| 787 | 0 | |n http://www.oncologyreviews.org/index.php/or/article/view/324 | |
| 787 | 0 | |n https://doaj.org/toc/1970-5557 | |
| 787 | 0 | |n https://doaj.org/toc/1970-5565 | |
| 856 | 4 | 1 | |u https://doaj.org/article/d4e077f9940c48a8880784b7e7c30b23 |z Connect to this object online. |